Evidence map›Paper›PMID 29239137›Full record

ReviewCancer medicine2018

Medical management of gastric cancer: a 2017 update.

Nikolaos Charalampakis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Tolia, Dimitrios Schizas, Theodore Liakakos, Elena Elimova, Jaffer A Ajani, Amanda Psyrri

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 7 pooled it
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 7 syntheses or guidelines pooled it, 191 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Observational
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Nikolaos CharalampakisDepartment of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.ORCID 0000-0002-8756-9659
Panagiota EconomopoulouDepartment of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Ioannis KotsantisDepartment of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Maria ToliaRadiation Oncology Department, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece.
Dimitrios SchizasFirst Department of Surgery, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Theodore LiakakosFirst Department of Surgery, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Elena ElimovaDepartment of Medicine, Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
Jaffer A AjaniDepartment of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Amanda PsyrriDepartment of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
National and Kapodistrian University of Athens · GRThe University of Texas MD Anderson Cancer Center · USUniversity of Thessaly · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence-based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer.

Indexed as

GastrectomyAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorChemotherapy, AdjuvantClinical Trials, Phase III as TopicGlobal Burden of DiseaseHumansMolecular Targeted TherapyPrognosisRandomized Controlled Trials as TopicStomach NeoplasmsBiomarkers, TumorGastric cancermolecular characteristicsmultimodality treatment approachnew therapiespathologic characteristics

Identifiers

PMID29239137
PMCPMC5773977
OpenAlexW2775790492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.